Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase (ALK)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT06256484
What this trial is testing

Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics 1
Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Not applicableAvailableNCT04146571
What this trial is testing

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK Gene Rearrangement Positive
Xcovery Holdings, Inc.
Large-scale testing (Phase 3)Study completedNCT01639001
What this trial is testing

Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Pfizer 207
Large-scale testing (Phase 3)UnknownNCT04009317
What this trial is testing

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 260
Early research (Phase 1)Study completedNCT01284192
What this trial is testing

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Who this might be right for
Advanced MalignanciesPositive for Anaplastic Lymphoma KinasePositive for Proto-Oncogene Tyrosine-Protein Kinase ROS+2 more
Astellas Pharma Inc 46
Testing effectiveness (Phase 2)Looking for participantsNCT06620835
What this trial is testing

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

Who this might be right for
NSCLC
Groupe Francais De Pneumo-Cancerologie 45
Testing effectiveness (Phase 2)Looking for participantsNCT05384626
What this trial is testing

Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid Tumor
Nuvalent Inc. 840
Not applicableUnknownNCT01257308
What this trial is testing

Research of the EML4-ALK Gene Expression in the Pleural Effusion or Tumor Tissue From Lung Cancer Patients

Who this might be right for
Lung Cancer Patients
Taipei Medical University WanFang Hospital 100
Large-scale testing (Phase 3)Study completedNCT02737501
What this trial is testing

ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Non-small Cell Lung CancerLung CancerAdvanced Malignancies+1 more
Ariad Pharmaceuticals 275
Large-scale testing (Phase 3)Not Yet RecruitingNCT06254599
What this trial is testing

SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 255
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Not applicableStudy completedNCT03546894
What this trial is testing

Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Who this might be right for
Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung
Takeda 111
Testing effectiveness (Phase 2)Ended earlyNCT02465528
What this trial is testing

Ceritinib Rare Indications Study in ALK+ Tumors

Who this might be right for
Tumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more
Novartis Pharmaceuticals 22
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Not applicableNo Longer AvailableNCT03066661
What this trial is testing

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Who this might be right for
Cancers With NTRK, ROS1, or ALK Gene Fusions
Hoffmann-La Roche
Testing effectiveness (Phase 2)Study completedNCT03647488
What this trial is testing

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Not applicableStudy completedNCT01700582
What this trial is testing

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Who this might be right for
Carcinoma, Non-Small-Cell LungALK Gene MutationKRAS Gene Mutation+1 more
Intergroupe Francophone de Cancerologie Thoracique 17,664
Next Page